312 related articles for article (PubMed ID: 9521062)
1. The induction of a protective response in Leishmania major-infected BALB/c mice with anti-CD40 mAb.
Ferlin WG; von der Weid T; Cottrez F; Ferrick DA; Coffman RL; Howard MC
Eur J Immunol; 1998 Feb; 28(2):525-31. PubMed ID: 9521062
[TBL] [Abstract][Full Text] [Related]
2. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
[TBL] [Abstract][Full Text] [Related]
3. Interaction of Macrophage Antigen 1 and CD40 Ligand Leads to IL-12 Production and Resistance in CD40-Deficient Mice Infected with Leishmania major.
Okwor I; Jia P; Uzonna JE
J Immunol; 2015 Oct; 195(7):3218-26. PubMed ID: 26304989
[TBL] [Abstract][Full Text] [Related]
4. The development of a Th1-type response and resistance to Leishmania major infection in the absence of CD40-CD40L costimulation.
Padigel UM; Perrin PJ; Farrell JP
J Immunol; 2001 Nov; 167(10):5874-9. PubMed ID: 11698463
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-4-independent acceleration of cutaneous leishmaniasis in susceptible BALB/c mice following treatment with anti-CTLA4 antibody.
Heinzel FP; Maier RA
Infect Immun; 1999 Dec; 67(12):6454-60. PubMed ID: 10569763
[TBL] [Abstract][Full Text] [Related]
6. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.
Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G
Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of IL-9-expression after infection with Leishmania major in susceptible and resistant mice.
Gessner A; Blum H; Röllinghoff M
Immunobiology; 1993 Dec; 189(5):419-35. PubMed ID: 8125519
[TBL] [Abstract][Full Text] [Related]
8. Anti-leishmania effector functions of CD4+ Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice.
Louis JA; Conceiçao-Silva F; Himmelrich H; Tacchini-Cottier F; Launois P
Adv Exp Med Biol; 1998; 452():53-60. PubMed ID: 9889959
[TBL] [Abstract][Full Text] [Related]
9. An immunomodulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with Leishmania major.
Tacchini-Cottier F; Zweifel C; Belkaid Y; Mukankundiye C; Vasei M; Launois P; Milon G; Louis JA
J Immunol; 2000 Sep; 165(5):2628-36. PubMed ID: 10946291
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
[TBL] [Abstract][Full Text] [Related]
11. Despite increased CD4+Foxp3+ cells within the infection site, BALB/c IL-4 receptor-deficient mice reveal CD4+Foxp3-negative T cells as a source of IL-10 in Leishmania major susceptibility.
Nagase H; Jones KM; Anderson CF; Noben-Trauth N
J Immunol; 2007 Aug; 179(4):2435-44. PubMed ID: 17675505
[TBL] [Abstract][Full Text] [Related]
12. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease.
Himmelrich H; Launois P; Maillard I; Biedermann T; Tacchini-Cottier F; Locksley RM; Röcken M; Louis JA
J Immunol; 2000 May; 164(9):4819-25. PubMed ID: 10779790
[TBL] [Abstract][Full Text] [Related]
13. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity.
Kamanaka M; Yu P; Yasui T; Yoshida K; Kawabe T; Horii T; Kishimoto T; Kikutani H
Immunity; 1996 Mar; 4(3):275-81. PubMed ID: 8624817
[TBL] [Abstract][Full Text] [Related]
14. CD40 ligand is required for protective cell-mediated immunity to Leishmania major.
Campbell KA; Ovendale PJ; Kennedy MK; Fanslow WC; Reed SG; Maliszewski CR
Immunity; 1996 Mar; 4(3):283-9. PubMed ID: 8624818
[TBL] [Abstract][Full Text] [Related]
15. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
[TBL] [Abstract][Full Text] [Related]
16. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis.
Akiba H; Miyahira Y; Atsuta M; Takeda K; Nohara C; Futagawa T; Matsuda H; Aoki T; Yagita H; Okumura K
J Exp Med; 2000 Jan; 191(2):375-80. PubMed ID: 10637281
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CD40-induced N-Ras activation reduces leishmania major infection.
Chakraborty S; Srivastava A; Jha MK; Nair A; Pandey SP; Srivastava N; Kumari S; Singh S; Krishnasastry MV; Saha B
J Immunol; 2015 Apr; 194(8):3852-60. PubMed ID: 25786685
[TBL] [Abstract][Full Text] [Related]
18. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
Bretscher PA; Ogunremi O; Menon JN
Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
[TBL] [Abstract][Full Text] [Related]
19. BALB/c mice bearing a transgenic IL-12 receptor beta 2 gene exhibit a nonhealing phenotype to Leishmania major infection despite intact IL-12 signaling.
Nishikomori R; Gurunathan S; Nishikomori K; Strober W
J Immunol; 2001 Jun; 166(11):6776-83. PubMed ID: 11359836
[TBL] [Abstract][Full Text] [Related]
20. Analysis of cytokine patterns produced by individual CD4+ lymph node cells during experimental murine leishmaniasis in resistant and susceptible mice.
Sommer F; Meixner M; Mannherz M; Ogilvie AL; Röllinghoff M; Lohoff M
Int Immunol; 1998 Dec; 10(12):1853-61. PubMed ID: 9885906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
